An RNA splicing technique that Stoke Therapeutics is developing led to the production of a protein that’s lacking in Dravet syndrome, a study in mice showed. Stoke discussed the approach at the Oligonucleotide & Peptide Therapeutics Conference in Boston, March 26-28. Dr. Charles R. Allerson, Stoke’s vice president of chemistry, delivered the presentation, which was titled “Targeted Augmentation of Nuclear … Continue reading Stoke’s RNA-focused Therapy Generates Protein Lacking in Dravet Syndrome, Mouse Study Shows